Neel Trivedi, MD
Hematology & Oncology · Camden, NJNPI 1467870113
Payments from drug & device makers
Across 79 payments — averaging $160.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$7K
- Taiho Oncology, Inc.$3K
- Incyte Corporation$484
- AstraZeneca$354
- Genentech, Inc.$300
- E.r. Squibb & Sons, L.L.C.$237
- plus $2K from 26 others
What the payments were for
- Consulting fees$9,36574%
- Food & beverage$3,25626%
- Education$851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 9 | $6,677 |
| Taiho Oncology, Inc. | 1 | $2,800 |
| Incyte Corporation | 6 | $484 |
| AstraZeneca | 9 | $354 |
| Genentech, Inc. | 3 | $300 |
| E.r. Squibb & Sons, L.L.C. | 2 | $237 |
| Tempus AI, Inc | 3 | $207 |
| Bristol Myers Squibb | 3 | $188 |
| Astellas Pharma US Inc | 8 | $188 |
| Gilead | 4 | $154 |
| Bayer | 3 | $150 |
| Ipsen Biopharmaceuticals, Inc | 1 | $123 |
| Sanofi | 1 | $120 |
| Jazz Pharmaceuticals Inc. | 1 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $98 |
| Novartis | 4 | $87 |
| Daiichi Sankyo Inc. | 2 | $56 |
| Myriad Genetic Laboratories, Inc. | 3 | $50 |
| Merck | 2 | $45 |
| Foundation Medicine, Inc. | 1 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Servier Pharmaceuticals LLC | 1 | $25 |
| Seagen Inc. | 1 | $24 |
| GSK | 1 | $23 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| AbbVie | 1 | $17 |
| Deciphera Pharmaceuticals Inc. | 1 | $16 |
| Adaptive Biotechnologies Corporation | 1 | $16 |
| Blueprint Medicines Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,706 in reported general payments places this provider in the 55th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 71 | $58,667 |
| Anastrozole | 14 | $629 |
| Prochlorperazine Maleate | 14 | $300 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Camden
- Ahmed Abou HusseinCamden$356K
- Tulin Budak AlpdoganCamden$268K
- Generosa GranaCamden$174K
- Bruno FangEast Brunswick$8.5M
- Charles FarberMorristown$4.6M
- Rajat BannerjiNew Brunswick$3.3M
- Eleonora TeplinskyParamus$2.6M
- Mohamad CherryMorristown$1.9M
- Evan NaylorManahawkin$1.3M
- James OrsiniBelleville$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.